Comparative intravitreal antibiotic therapy for experimental Enterococcus faecalis endophthalmitis
S. Choi, T. W. Hahn, G. Osterhout and T. P. O'Brien
Ocular Microbiology Laboratory, Wilmer Ophthalmological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
OBJECTIVE: To evaluate the most effective intravitreal antibiotic treatment
of vancomycin-sensitive and -resistant Enterococcus faecalis
endophthalmitis. DESIGN: Animal experiment. SETTING: Seventy-eight New
Zealand white rabbits received an intravitreal injection of 10(5)
vancomycin-sensitive or -resistant E faecalis organisms in one eye.
Infections were allowed to proceed 3 hours before dividing animals randomly
into the following treatment groups (n = 6, each): the vancomycin-sensitive
E faecalis model--(1) vancomycin (1 mg/0.1 mL), (2) combined vancomycin (1
mg/0.1 mL) and amikacin (0.4 mg/0.1 mL), (3) combined vancomycin (1 mg/0.1
mL) and gentamicin (0.1 mg/0.1 mL), (4) combined vancomycin (1 mg/0.1 mL)
and ceftazidime (2 mg/0.1 mL), (5) combined ampicillin (5 mg/0.1 mL) and
gentamicin (0.1 mg/0.1 mL), and (6) pristinamycin (1 mg/0.1 mL); and the
vancomycin-resistant E faecalis model--(1)same as above, excluding group 4.
Control groups received sterile balanced salt solution. Twenty-four hours
following intravitreal treatment, vitreous humor was collected for
quantitative bacteriological studies. RESULTS: Intravitreal therapy with
combined vancomycin and amikacin provided the most effective reduction of
vancomycin-sensitive E faecalis organisms compared with combined vancomycin
and gentamicin therapy (P =.10, Wilcoxon's rank sum test) or any other
treatment group (P < .01, Wilcoxon's rank sum test). For
vancomycin-resistant E faecalis endophthalmitis model, the combined
ampicillin and gentamicin therapy was the most effective, followed by the
combined vancomycin and amikacin therapy (P < .01, Wilcoxon's rank sum
test). CONCLUSIONS: Treatment with intravitreal vancomycin plus amikacin
and with intravitreal ampicillin plus gentamicin provide an effective
bactericidal therapy for severe experimental vancomycin-sensitive and
-resistant E faecalis endophthalmitis, respectively.